ArticleJAMA ophthalmology2013
Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.
Article in JAMA ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 53 citations in OpenAlex.
- Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.The oncologist · 2021Trial
- Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.JAMA ophthalmology · 2020Trial
- Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.Annals of translational medicine · 2024Article
- Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances.Journal of ophthalmology · 2024Article
- Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial.PloS one · 2022Article
- Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.American journal of ophthalmology case reports · 2020Article
- [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Periocular basal cell carcinoma - clinical perspectives.Oncology reviews · 2020Article
- [Young male patient with unusual space-occupying lesion of the lower eyelid].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Article
- Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.Current oncology reports · 2017Review
- Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.Plastic and reconstructive surgery. Global open · 2017Article
- Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.OncoTargets and therapy · 2017Review
- Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.World journal of clinical cases · 2014Review
- Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib.Autopsy & case reportsArticle
- Myths in the Diagnosis and Management of Orbital Tumors.Middle East African journal of ophthalmologyArticle
- Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.Ophthalmic plastic and reconstructive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.